Citizens Jmp Upgrades Allogene Therapeutics (NASDAQ:ALLO) to Outperform

Allogene Therapeutics (NASDAQ:ALLO) was upgraded by equities research analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating in a note issued to investors on Friday, Marketbeat.com reports. The firm presently has a $5.00 target price on the stock. Citizens Jmp’s target price points to a potential upside of 192.40% from the stock’s current price.

Several other brokerages have also commented on ALLO. Citigroup upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Finally, UBS Group started coverage on shares of Allogene Therapeutics in a research note on Wednesday. They set a “buy” rating and a $8.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $1.71 on Friday. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78. The firm’s fifty day moving average is $1.36 and its 200-day moving average is $1.26. The firm has a market cap of $384.29 million, a P/E ratio of -1.74 and a beta of 0.51.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. As a group, sell-side analysts anticipate that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total transaction of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares in the company, valued at approximately $1,608,762.96. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 13.20% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in Allogene Therapeutics during the 1st quarter valued at about $85,000. Goldman Sachs Group Inc. lifted its holdings in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after purchasing an additional 3,747,397 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock valued at $1,630,000 after buying an additional 952,158 shares during the last quarter. Harold Davidson & Associates Inc. grew its holdings in Allogene Therapeutics by 8.5% during the first quarter. Harold Davidson & Associates Inc. now owns 252,350 shares of the company’s stock worth $368,000 after buying an additional 19,735 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in Allogene Therapeutics during the second quarter worth $390,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: UBS initiated coverage with a Buy and $8 price target, citing upside to ALLO’s pipeline and potential validation of allogeneic CAR‑T if upcoming readouts are positive. UBS initiates coverage of Allogene Therapeutics (ALLO) with buy recommendation
• Positive Sentiment: Citizens JMP upgraded ALLO from Market Perform to Outperform and set a $5 target — another analyst vote that increases the stock’s visible upside and likely contributed to short‑term buying. Benzinga coverage of analyst action
• Positive Sentiment: Allogene’s own press release frames 2026 as a program‑defining year with multiple first‑half clinical readouts planned across oncology and autoimmune programs — this set of near‑term milestones increases binary upside if data are positive. Allogene Therapeutics Positions 2026 as a Program-Defining Year
• Neutral Sentiment: AAII explains the immediate price move, attributing it to the new analyst coverage and the company’s 2026 roadmap; useful read for traders seeking the narrative behind today’s jump. Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 18.13%
• Neutral Sentiment: Zacks compares ALLO to medical‑sector peers and discusses sector‑level performance this year — helpful context but not a direct catalyst. Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
• Neutral Sentiment: Globe and Mail ran an analysts‑insights piece that includes ALLO — provides additional perspective but no new company data. Analysts Offer Insights on Healthcare Companies

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.